Latest filing published 27 Mar 2012 for OSIRIS THERAPEUTICS, INC., €19k.
Insider track record
No signal scores available.
Closed purchases
Based on 21 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -37.1%Entry US$5.60 · Close at T+365 US$3.52
- -52.5%Entry US$6.40 · Close at T+365 US$3.04
- -65.6%Entry US$16.96 · Close at T+365 US$5.84
- -53.1%Entry US$21.68 · Close at T+365 US$10.16
- -55.6%Entry US$25.20 · Close at T+365 US$11.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Gregory Hurd Barnhill: trading record in brief
Gregory Hurd Barnhill is a declared insider at 2 companies; the most frequent names are Pure Bioscience, Inc. and Osiris Therapeutics, Inc. Over a trading history stretching from 12 April 2006 to 31 July 2012, the count stands at 70 filings.
Market trades split into 23 purchases (€593k) and 12 sales (€205k). Taken together, the purchases exceed the sales by €388k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 17 share grants and 5 option exercises.
The median purchase comes to €16k. For 21 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 29% of cases, with a median move of -9.3%. They describe history only and say nothing certain about the share price ahead.
On 2 August 2012 came the latest disclosure, a share grant for €4,238 in Pure Bioscience, Inc. The last insider purchase was made public on 1 July 2011, 5,609 days ago. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Gregory Hurd Barnhill
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,000 shares@ US$5.08Common StockSEC:0001179110-12-005794:0
- 50,000 shares@ US$0.7753Common StockSEC:0001079973-11-000551:0Canonical exit: 27 Sept 2011 (T+90)
- 25,000 shares@ US$0.8938Common StockSEC:0001079973-11-000532:0Canonical exit: 19 Sept 2011 (T+90)
- 25,000 shares@ US$7.20Common StockSEC:0001179110-11-009286:0Canonical exit: 1 Sept 2011 (T+90)
- 25,000 shares@ US$7.07Common StockSEC:0001179110-11-009286:1Canonical exit: 4 Sept 2011 (T+90)
- 50,000 shares@ US$1.65Common StockSEC:0001079973-11-000178:0
- 5,000 shares@ US$7.13Common StockSEC:0001179110-11-002829:0
- 50,000 shares@ US$0.53Common StockSEC:0001079973-11-000010:0
- 11,778 shares@ US$2.25Common StockSEC:0001079973-11-000010:1
- 2,780 shares@ US$2.24Common StockSEC:0001079973-10-001284:0
- 1,000 shares@ US$2.43Common StockSEC:0001079973-10-001284:1
- 897 shares@ US$2.17Common StockSEC:0001079973-10-001261:0
- 24,000 shares@ US$2.40Common StockSEC:0001079973-10-001252:0
- 1,500 shares@ US$2.51Common StockSEC:0001079973-10-001151:0
- 5,000 shares@ US$1.84Common StockSEC:0001079973-10-000753:0Canonical exit: 5 Oct 2010 (T+90)
- 7,400 shares@ US$2.52Common StockSEC:0001079973-10-000736:0
- 5,000 shares@ US$6.46Common StockSEC:0001179110-10-009640:0
- 5,000 shares@ US$2.72Common StockSEC:0001079973-10-000479:0Canonical exit: 13 Jul 2010 (T+90)
- 10,000 shares@ US$2.02Common StockSEC:0001079973-10-000437:0Canonical exit: 5 Jul 2010 (T+90)
- 10,000 shares@ US$1.80Common StockSEC:0001079973-10-000320:0Canonical exit: 13 Jun 2010 (T+90)
- 40,000 shares@ US$1.36Common StockSEC:0001079973-10-000074:0
- 28,492 shares@ US$1.35Common StockSEC:0001079973-10-000074:1
- 3,500 shares@ US$1.50Common StockSEC:0001079973-10-000045:0
- 29,410 shares@ US$1.44Common StockSEC:0001079973-10-000045:1
- 27,090 shares@ US$1.55Common StockSEC:0001079973-10-000045:2
25 of 65 declarations
